Astrana Health, Inc. (NASDAQ:ASTH) Receives $65.17 Average Target Price from Analysts

Astrana Health, Inc. (NASDAQ:ASTH) has been assigned a consensus recommendation of “Buy” from the eight analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $65.17.

Several research firms have recently issued reports on ASTH. Stifel Nicolaus upped their price objective on shares of Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Robert W. Baird lifted their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Truist Financial upped their target price on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, August 9th. BTIG Research lifted their price target on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. Finally, TD Cowen initiated coverage on shares of Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 price target on the stock.

Astrana Health Price Performance

NASDAQ:ASTH opened at $42.11 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The stock has a market capitalization of $2.37 billion, a P/E ratio of 32.39, a P/E/G ratio of 1.95 and a beta of 1.24. The company’s 50-day simple moving average is $54.17 and its 200-day simple moving average is $47.94. Astrana Health has a fifty-two week low of $32.32 and a fifty-two week high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the previous year, the company earned $0.47 earnings per share. On average, equities analysts anticipate that Astrana Health will post 1.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

A number of institutional investors have recently added to or reduced their stakes in ASTH. State Street Corp purchased a new stake in shares of Astrana Health during the third quarter worth approximately $91,966,000. Geode Capital Management LLC purchased a new stake in shares of Astrana Health during the third quarter worth $58,995,000. FMR LLC purchased a new stake in shares of Astrana Health during the third quarter worth $48,413,000. SteelPeak Wealth LLC acquired a new stake in shares of Astrana Health in the third quarter valued at about $39,398,000. Finally, Loomis Sayles & Co. L P purchased a new position in shares of Astrana Health in the third quarter worth about $30,251,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.